<p>美國銀行證券分析師 Jason Zemansky 今天對 Lyell Immunopharma 維持了賣出評級，並設定了 12.00 美元的目標價。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
<p>根據 TipRanks，Zemansky 是一位五星級分析師，平均回報率為 21.3%，成功率為 58.82%。Zemansky 覆蓋醫療保健行業，專注於 Biogen、Cytokinetics 和 BridgeBio Pharma 等股票。</p>
<p>市場普遍認為，Lyell Immunopharma 的分析師共識評級為適度買入，平均目標價為 36.80 美元。</p>

LYEL

<p>美國銀行證券分析師 Jason Zemansky 重申了對 Lyell Immunopharma（LYEL）的賣出評級，目標價為 12.00 美元。Zemansky 是一位五星級分析師，平均回報率為 21.3%，成功率為 58.82%。對 Lyell Immunopharma 的整體分析師共識為適度買入，平均目標價為 36.80 美元</p>

<p>Bank of America Securities analyst Jason Zemansky maintained a Sell rating on Lyell Immunopharma today and set a price target of $12.00.</p>
<div class="lb-trans"><p>美國銀行證券分析師 Jason Zemansky 今天對 Lyell Immunopharma 維持了賣出評級，並設定了 12.00 美元的目標價。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
</div><p>According to TipRanks, Zemansky is a 5-star analyst with an average return of 21.3% and a 58.82% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Biogen, Cytokinetics, and BridgeBio Pharma.</p>
<div class="lb-trans"><p>根據 TipRanks，Zemansky 是一位五星級分析師，平均回報率為 21.3%，成功率為 58.82%。Zemansky 覆蓋醫療保健行業，專注於 Biogen、Cytokinetics 和 BridgeBio Pharma 等股票。</p>
</div><p>The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lyell Immunopharma with a $36.80 average price target.</p>
<div class="lb-trans"><p>市場普遍認為，Lyell Immunopharma 的分析師共識評級為適度買入，平均目標價為 36.80 美元。</p>
</div>

Bank of America Securities Reaffirms Their Sell Rating on Lyell Immunopharma (LYEL)

Tip Ranks

Lyell Immunopharma

美國銀行

Biogen

細胞動力

Bridgebio Pharma

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

美國銀行證券重申了對 Lyell Immunopharma（LYEL）的賣出評級